Skip to content

Calidi Biotherapeutics, Inc.

CLDI CLDWW

CIK 0001855485 · Biological Products, (No Diagnostic Substances) · NYSE, OTC

  • Calidi Biotherapeutics, Inc. (until 2026-06-18)
  • First Light Acquisition Group, Inc. (until 2023-09-19)
← back to feed
Revenue (TTM)
$45K
Q1 May 2026
Net Income (TTM)
−$19.96M
+10.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$6.84
+83.3% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-44,357.8%
Q1 May 2026
Net Margin
-44,351.1%
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$9.6M
Q1 May 2026
Total Debt
$623K
Q1 May 2026
Shares Outstanding
19.31M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings